Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Biochemical and Molecular Characterization of Marstacimab and TFPI Pathways
    Release Date:
    Review Process: Pfizer Internal
    Research Rare Disease Brazil, China, Germany, Italy, Japan, Korea, Netherlands, Saudi Arabia, Spain, Turkey, USA, United Kingdom
    Optimizing RSV diagnosis by improving RSV detection in patients admitted to ED/hospitalized due to respiratory symptoms
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines Austria, Belgium, Bulgaria, Czech Republic, Finland, Greece, Ireland, Israel, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Sweden, Switzerland
    Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology USA
    Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUC
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Advancing Genomic Competence and Patient Centered Care in Metastatic Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom
    AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction Management
    Release Date:
    Review Process: Pfizer Internal
    Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan
    Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-posit
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology United States Minor Outlying I
    OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic Malignancies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology China
    Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory Outcome
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Implementing Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease USA
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Phase I/II Clinical Trials of Axitinib in the Treatment of Melanoma, Hepatocellular Carcinoma and Colorectal Cancer
    Release Date:
    Partner:

    NCCN

    Review Process: Expert Review Panel
    Research Oncology All, USA
    Advances in Moderate-to-Severe Atopic Dermatitis for Dermatologists
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Incorporating Biosimilar Treatment Options in Solid Tumor Education Programs
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    NSCLC – Current Practice Considerations
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Mexico, Monaco, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, USA, United Kingdom
    Gram Negatives Pathogens & Antimicrobial Resistance: Local Data Generation in Latin America
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Guatemala, Honduras, Mexico, Panama, Peru, Uruguay
    Addressing Health Disparities in Inflammatory Bowel Disease
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology USA
    Enduring SpA Programs
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology All
    Atopic Dermatitis Patient Education
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Knowledge Gaps in Updated Pneumococcal Immunization Recommendations
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Prostate Cancer Disparities Project
    Release Date:
    Partner:

    American Cancer Society

    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    Telehealth Solutions in Rheumatoid Arthritis for Improving Education and Patient Care (Emerging Markets)
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology All
    Telehealth Solutions in Atopic Dermatitis for Improving Education and Patient Care (Emerging Markets)
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology All